Clinical Trials Browser

Active not recruiting × Interventional × Tumor-Agnostic × Clear all

NCT03030378 2026-03-19

Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors

Phase 1 Active not recruiting

Neoplasm Metastasis

NCT04317105 2026-03-18

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN

Phase 1/2 Active not recruiting

Neoplasm Metastasis

NCT05554341 2026-03-18

Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial

Phase 2 Active not recruiting

Neoplasm Metastasis

NCT04958239 2026-03-17

A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer

Phase 1 Active not recruiting

Neoplasms

NCT07474168 2026-03-16

T Cell Receptor Gene-Engineered and Dominant Negative TGF-β Receptor T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

Phase 1 Active not recruiting

Neoplasms

NCT04318886 2026-03-13

Lay Coach-Led Early Palliative Care for Underserved Advanced Cancer Caregivers: The Project ENABLE Cornerstone RCT

Phase 3 Active not recruiting

Neoplasm Metastasis

NCT02908906 2026-03-12

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers

Phase 1/2 Active not recruiting

Neoplasms

NCT04803604 2026-03-12

CASCADE

Phase NA Active not recruiting

Neoplasms

NCT05763797 2026-03-11

Developing a Culturally Relevant Supportive Care Program for Black Patients Dealing With Advanced Cancer

Phase NA Active not recruiting

Neoplasms

NCT05993299 2026-03-11

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Phase 2 Active not recruiting

7 enrolled 15 charts

Neoplasms

NCT06864260 2026-03-11

PREEMpT

Phase NA Active not recruiting

Neoplasms

NCT05707910 2026-03-09

Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors

Phase 1 Active not recruiting

Neoplasms

NCT06549153 2026-03-09

ACT-Together (Acting on Cancer Testing-Together)

Phase NA Active not recruiting

Neoplasms

NCT01428895 2026-03-06

Femoral Bone Metastases

Phase NA Active not recruiting

Neoplasms

NCT05611632 2026-03-05

NHS-Galleri

Phase NA Active not recruiting

142,318 enrolled

Neoplasms

NCT04913259 2026-03-03

TS-PAC

Phase NA Active not recruiting

33 enrolled 8 charts

Neoplasms

NCT04294628 2026-02-27

Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer

Phase 1 Active not recruiting

Neoplasm Metastasis

NCT04538482 2026-02-27

DINING

Phase NA Active not recruiting

Neoplasms

NCT03203525 2026-02-25

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

Phase 1 Active not recruiting

Neoplasms

NCT06703346 2026-02-25

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Phase 2 Active not recruiting

Neoplasms

NCT00750841 2026-02-23

Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours

Phase 1 Active not recruiting

Neoplasm Metastasis

NCT05823740 2026-02-20

Measuring Changes in Body Composition and Physical Function in Patients With Childhood Cancers

Phase NA Active not recruiting

Neoplasms

NCT03927885 2026-02-19

Open Labeled Placebo in Reducing Cancer Related Fatigue in Patients With Advanced Cancer

Phase 2/3 Active not recruiting

Neoplasm Metastasis

NCT04150900 2026-02-19

1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck

Phase 2 Active not recruiting

7 enrolled 11 charts

Carcinoma, Squamous Cell

NCT05396833 2026-02-19

Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)

Phase 1 Active not recruiting

Neoplasm Metastasis

NCT04150939 2026-02-17

Cryoablation for the Treatment of Metastatic Cancer

Phase NA Active not recruiting

Neoplasm Metastasis

NCT05117931 2026-02-17

A Study of Amivantamab in People With Esophagogastric Cancer

Phase 2 Active not recruiting

Neoplasm Metastasis

NCT06340906 2026-02-13

Electroacupuncture in Symptom Management After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

Phase NA Active not recruiting

Neoplasms

NCT04078295 2026-02-10

A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor

Phase 1/2 Active not recruiting

Neoplasms

NCT03260023 2026-02-05

Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers

Phase 1/2 Active not recruiting

143 enrolled 24 charts

Neoplasms

NCT02584933 2026-02-03

Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study

Phase 4 Active not recruiting

Neoplasms

NCT04733469 2026-02-02

EMPOWER 3

Phase NA Active not recruiting

Neoplasms

NCT06077877 2026-02-02

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

Phase 1/2 Active not recruiting

Neoplasms

NCT06926972 2026-02-02

NOURISH

Phase NA Active not recruiting

Neoplasms

NCT03964727 2026-01-30

TROPiCS-03

Phase 2 Active not recruiting

223 enrolled 31 charts

Neoplasm Metastasis

NCT04170153 2026-01-30

Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

Phase 1 Active not recruiting

Neoplasm Metastasis

NCT03768063 2026-01-29

IMbrella B

Phase 3 Active not recruiting

Neoplasms

NCT03436290 2026-01-28

SCOPE

Phase NA Active not recruiting

236 enrolled 10 charts

Neoplasms

NCT06693128 2026-01-28

Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer

Phase 2 Active not recruiting

Adenocarcinoma

NCT04208347 2026-01-23

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

Phase 2/3 Active not recruiting

Adenocarcinoma

NCT05283577 2026-01-23

EAST

Phase NA Active not recruiting

Neoplasms

NCT05455606 2026-01-22

Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment

Phase NA Active not recruiting

Neoplasm Metastasis

NCT03096093 2026-01-20

Investigation of a Therapeutic Vaccine (ACIT-1) in Cancer

Phase 1/2 Active not recruiting

Neoplasms

NCT03148418 2026-01-13

A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)

Phase 3 Active not recruiting

Neoplasms

NCT04062552 2026-01-13

Learning Collaborative Versus Technical Assistance in Delivering a Palliative Care Program to Patients With Advanced Cancer and Their Caregivers

Phase NA Active not recruiting

Neoplasm Metastasis

NCT03065387 2026-01-12

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

Phase 1 Active not recruiting

Neoplasm Metastasis

NCT05273554 2026-01-12

A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma

Phase 1 Active not recruiting

Adenocarcinoma, Neoplasms

NCT04795661 2026-01-07

IMHOTEP

Phase 2 Active not recruiting

Neoplasms

NCT05112965 2026-01-07

An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)

Phase 3 Active not recruiting

Neoplasms

NCT02560636 2026-01-06

PLUMMB

Phase 1 Active not recruiting

Neoplasm Metastasis